Tyra Biosciences (TYRA) Stock Forecast & Price Target

Tyra Biosciences is supported by a differentiated FGFR3-selective platform that could address multiple large markets, including urothelial cancers and achondroplasia, while aiming to improve on the toxicity and resistance limitations of first-generation pan-FGFR inhibitors. The clean 60 mg safety profile, with 0/22 Grade 3 treatment-related adverse events and no clinically significant hyperphosphatemia, nail, or ocular toxicity, strengthens confidence in chronic dosing and preserves the adjuvant IR-NMIBC opportunity despite the SURF302 efficacy miss. In achondroplasia, BEACH301 has already cleared five sentinel doses without a reported safety signal, and the valuation view is underpinned by UTUC, ACH, platform value, and net cash even after reflecting the $400M public offering and dilution.

Tyra Biosciences is viewed negatively because its lead programs have yet to prove that early signals translate into durable, clinically compelling efficacy against stronger benchmarks. In BEACH301, the company still needs >6cm/year absolute height velocity across most children without chronic pediatric safety issues, while SURF302’s 57% 3-month complete response at 60mg missed a ≥70% bar and fell below erdafitinib comparators, weakening urothelial probability of approval to 20% from 45%. These misses narrow the commercial outlook, raise reliance on later dose-response data, and leave key value drivers dependent on unproven readouts rather than established efficacy.